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Abstract 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a devastating 
autosomal recessive disorder due to mutations in TYMP, which cause loss of function of 
thymidine phosphorylase (TP), nucleoside accumulation in plasma and tissues and 
mitochondrial dysfunction. The clinical picture includes progressive gastrointestinal 
dysmotility, cachexia, ptosis and ophthalmoparesis, peripheral neuropathy and diffuse 
leukoencephalopathy, which usually lead to death in early adulthood. Therapeutic options 
are currently available in clinical practice (allogeneic hematopoietic stem cell transplantation 
and carrier erythrocyte entrapped TP therapy) and newer, promising therapies are expected 
in the near future. However, successful treatment is strictly related to early diagnosis. We 
report on an incomplete MNGIE phenotype in a young man harboring the novel 
heterozygote c.199 C>T (Q67X) mutation in exon 2, and the previously reported c.866 A>C 
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(E289A) mutation in exon 7 in TYMP. The correct diagnosis was achieved many years after 
the onset of symptoms and unfortunately, the patient died soon after diagnosis because of 
multiorgan failure due to severe malnutrition and cachexia before any therapeutic option 
could be tried. To date, early diagnosis is essential to ensure that patients have the 
opportunity to be treated. MNGIE should be suspected in all patients who present with both 
gastrointestinal and nervous system involvement, even if the classical complete phenotype 
is lacking. 
 
Introduction 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare, 
devastating disease that usually manifests in childhood and leads to death at a mean 
age of 35 years [1]. It is clinically characterized by progressive gastrointestinal 
dysfunction, cachexia, ptosis and ophthalmoparesis, peripheral neuropathy and diffuse 
leukoencephalopathy [1, 2]. However, patients with an atypical phenotype and variable 
onset, course and severity have also been described [3–5]. 
MNGIE is caused by mutations in the TYMP gene encoding thymidine phosphorylase 
(TP) [6]. Since TYMP was discovered as the causative gene of MNGIE, more than 60 
different mutations associated with fewer than 250 cases have been reported [7]. Loss 
of TP activity determines marked elevation in thymidine and deoxyuridine levels in 
body fluids, nucleotide pool imbalance, subsequent instability of mitochondrial DNA 
(mtDNA) and impairment of the mitochondrial respiratory chain [1, 8]. 
We report the case of a young Caucasian patient with an incomplete MNGIE 
phenotype who harbored a novel disruptive TYMP mutation. His disease was diagnosed 
late, thus making any therapeutic option useless. Despite the current availability of 
effective treatment options such as allogeneic hematopoietic stem cell transplantation 
[9] and carrier erythrocyte entrapped TP therapy [10] as well as the promising future 
therapeutic approaches, e.g. gene therapy [11], it is essential to achieve early diagnosis 
to avoid the cumulative effects of imbalanced nucleosides on mtDNA and to prevent as 
much mitochondrial damage as possible [1, 8, 12]. 
Case Presentation 
Since he was 7, our 24-year-old patient had complained of intermittent postprandial vomiting and 
gastrointestinal dysmotility with alternating episodes of diarrhea and constipation that led to 
progressive weight loss over the years. He presented with severe cachexia (BMI 11.15) and numbness 
in the extremities of all 4 limbs. Neurological examination showed absence of deep tendon reflexes, 
length-dependent decreased proprioception and vibratory sensation, mild generalized weakness and 
diffuse muscle atrophy. He did not have ophthalmoparesis or ptosis. 
Electroencephalography was normal and a brain MRI showed diffuse leukoencephalopathy (fig. 
1a, b). Electroneurography and electromyography were not performed. No cardiac, renal or hepatic 
involvement was reported.  
Despite the lack of eye movement involvement, MNGIE was suspected and confirmed by 
measuring plasma thymidine and deoxyuridine [6 μmol/l (normal values <0.05) and 17 μmol/l 
(normal values <0.05), respectively] as well as TP activity in platelets [4 nmol/h/mg protein (normal 
values 377–1,320)]. 
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TYMP sequence analysis showed the novel heterozygote c.199 C>T (Q67X) mutation in exon 2 (fig. 
2a) and the previously reported c.866 A>C (E289A) mutation in exon 7 (fig. 2b) (GenBank reference 
sequence NM_001113755.1), thus genetically proving the diagnosis of MNGIE. The novel mutation 
leads to a change from glutamine to stop codon and was not detected in 200 ethnically matched 
control chromosomes by direct gene sequencing. 
Unfortunately, despite parenteral nutrition, the patient died of multiorgan failure due to severe 
malnutrition and cachexia a few weeks after diagnosis before any therapeutic option could be tried. A 
family history was not available. 
Discussion 
MNGIE is a multisystem autosomal recessive disorder mainly characterized by 
gastrointestinal and central/peripheral nervous system involvement [1]. 
Gastrointestinal dysmotility, abdominal pain and distension, diarrhea, progressive 
weight loss and severe cachexia are the prominent features of the disease, associated 
with ptosis and ophthalmoparesis, peripheral neuropathy and diffuse 
leukoencephalopathy [1, 2]. Patients usually die of complications resulting from their 
gastrointestinal disorders and inadequate nutritional status [1]. Diagnosis is achieved 
by demonstrating high plasma, urine thymidine and deoxyuridine concentrations, 
reduced TP enzyme activity and pathogenic mutations in TYMP [8]. Disease-related 
TYMP mutations determine loss of TP function, subsequent mitochondrial nucleotide 
pool imbalance, mtDNA instability and impairment of the mitochondrial genome 
replication [8]. A relationship between the clinical phenotype of MNGIE and TP activity 
is generally acknowledged: <10% of the normal activity causes typical MNGIE, 10–20% 
residual activity produces less severe late-onset phenotypes and >30% activity does 
not cause overt disease [13, 14]. However, there are relevant exceptions to this rule. 
Late-onset or less severe phenotypes in patients with greatly reduced or virtually 
absent TP activity have been reported [3, 5]. Intrafamilial phenotypical variability, 
ranging from extremely severe to very mild clinical pictures, has also been described, 
thus adding further difficulties in predicting disease evolution and prognosis [5, 7].  
The mutations reported herein, including the novel Q67X nonsense mutation, cause 
a profound deficiency in TP activity (4 nmol/h/mg protein). This may explain the 
severe phenotype in our patient. Interestingly, ophthalmoplegia, which is a 
fundamental element in suspecting the disease, was absent in this patient and may have 
contributed to the delay in diagnosis. Although most patients present with the classical 
phenotype and report the first symptoms already in childhood, the correct diagnosis is 
usually established years later [5]. A late diagnosis of the disease greatly reduces the 
chances of a positive outcome after therapy because patients start treatment when they 
are already in poor health and therefore have limited capacities to tolerate therapy and 
combat disease-related complications [5, 15]. The available therapeutic procedures aim 
to eliminate the toxic levels of thymidine and deoxyuridine by restoring at least partial 
TP activity. The earlier patients are treated, the less organ damage there is and the 
better the outcome will be [1, 9, 14]. In our patient, the correct diagnosis was achieved 
too late when multisystem involvement was so severe that it led to his death within a 
few weeks.  
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Conclusion 
Despite the enormous efforts in optimizing therapies for MNGIE, one must not 
ignore the need to achieve a correct diagnosis as soon as possible. MNGIE should be 
suspected and TP activity and nucleoside levels measured in all patients who present 
with both gastrointestinal and nervous system involvement, even if the classical 
complete phenotype is lacking. Early identification of patients can save lives. 
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Fig. 1. Brain MRIs with fluid attenuated inversion recovery. The images show sparing of the basal 
ganglia and corpus callosum (a) as well as diffuse leukoencephalopathy in the semioval centers (b). 
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Fig. 2. Electropherogram showing the two mutations in TYMP, namely a the heterozygote c.199 C>T 
mutation (arrow) and b the heterozygote c.866 A>C mutation (arrow). 
 
References 
1 Garone C, Tadesse S, Hirano M: Clinical and genetic spectrum of mitochondrial neurogastrointestinal 
encephalomyopathy. Brain 2011;134:3326–3332. 
2 Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, Connolly AM, Verloes A, 
Guimarães J, Maillard I, Hamano H, Donati MA, Semrad CE, Russell JA, Andreu AL, Hadjigeorgiou GM, Vu 
TH, Tadesse S, Nygaard TG, Nonaka I, Hirano I, Bonilla E, Rowland LP, DiMauro S, Hirano M: 
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to 
thymidine phosphorylase mutations. Ann Neurol 2000;47:792–800. 
3 Martín MA, Blázquez A, Martí R, Bautista J, Lara MC, Cabello A, Campos Y, Belda O, Andreu AL, Arenas J: 
Lack of gastrointestinal symptoms in a 60-year-old patient with MNGIE. Neurology 2004;63:1536–1537. 
4 Massa R, Tessa A, Margollicci M, Micheli V, Romigi A, Tozzi G, Terracciano C, Piemonte F, Bernardi G, 
Santorelli FM: Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine 
phosphorylase activity. Neuromuscul Disord 2009;19:837–840. 
5 Filosto M, Scarpelli M, Tonin P, Testi S, Cotelli MS, Rossi M, Salvi A, Grottolo A, Vielmi V, Todeschini A, 
Fabrizi GM, Padovani A, Tomelleri G: Pitfalls in diagnosing mitochondrial neurogastrointestinal 
encephalomyopathy. J Inherit Metab Dis 2011;34:1199–1203. 
6 Nishino I, Spinazzola A, Hirano M: Thymidine phosphorylase gene mutations in MNGIE, a human 
mitochondrial disorder. Science 1999;283:689–692. 
7 Libernini L, Lupis C, Mastrangelo M, Carrozzo R, Santorelli FM, Inghilleri M, Leuzzi V: Mitochondrial 
Neurogastrointestinal Encephalomyopathy: novel pathogenic mutations in thymidine phosphorylase 
gene in two Italian brothers. Neuropediatrics 2012;43:201–218. 
8 Martí R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M: Definitive diagnosis of mitochondrial 
neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem 2004;50:120–124. 
9 Halter J, Schüpbach WM, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, 
Lehmann T, Mandel H, Marti R, Mattle H, Orchard K, Savage D, Sue CM, Valcarcel D, Gratwohl A, Hirano 
M: Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a 
standardized approach. Bone Marrow Transplant 2011;46:330–337. 
 Case Rep Neurol 2012;4:248–253 
DOI: 10.1159/000346260 
Published online: 
December 20, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
 
253 
10 Moran NF, Bain MD, Muquit MM, Bax BE: Carrier erythrocyte entrapped thymidine phosphorylase 
therapy for MNGIE. Neurology 2008;71:686–688. 
11 Torres-Torronteras J, Gómez A, Eixarch H, Palenzuela L, Pizzorno G, Hirano M, Andreu AL, Barquinero J, 
Martí R: Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a 
murine model of MNGIE. Gene Ther 2011;18:795–806. 
12 Scarpelli M, Cotelli MS, Mancuso M, Tomelleri G, Tonin P, Baronchelli C, Vielmi V, Gregorelli V, 
Todeschini A, Padovani A, Filosto M: Current options in the treatment of mitochondrial diseases. Recent 
Pat CNS Drug Discov 2010;5:203–209. 
13 Martí R, Verschuuren J, Buchman A, Hirano I, Tadesse S, van Kuilenburg AB, van Gennip AH, Poorthuis 
BJ, Hirano M: Late-onset MNGIE due to partial loss of thymidine phosphorylase activity. Ann Neurol 
2005;58:649–652. 
14 Hirano M, Garone C, Quinzii C: CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders. 
Biochim Biophys Acta 2012;1820:625–631. 
15 Filosto M, Scarpelli M, Tonin P, Lucchini G, Pavan F, Santus F, Parini R, Donati MA, Cotelli MS, Vielmi V, 
Todeschini A, Canonico F, Tomelleri G, Padovani A, Rovelli A: Course and management of allogeneic stem 
cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 
2012;259:2699–2706. 
